In March 2012 Candore was in the midst of a rare viral epidemic. Viroblax is one of the drugs used in the treatment of this epidemic and Gentura is under severe pressure from the government to subsidize Viroblax. It is for this reason that Gentura is in breach of its contract with Cad Mex Pharma. Cadmex gave Gentura the rights to Viroblax which is a drug used in the treatment of severe viral infections however subsidized production of Viroblax would violate the payment terms of the contract between Gentura and Cadmex.
There are a few remedies that may be available for this breach of contract between Gentura and Cad Mex. One of these remedies would involve Gentura paying CadMex the royalties and other fees they owed them after the viral epidemic was under control and there was no longer a need for subsidized production. This however would mean that gentura would be losing money because they would not be making as much profit off of viroblax but at the same time they would still owe Cadmex just as much money as usual. The second remedy would involve Gentura ignoring the governments request to subsidize Viroblax and continuing to sell it for the normal price. The drawbacks to this remedy could be catastrophic. If Gentura refused to subsidize Viroblax countless numbers of lives in Candore could be lost.
Gentura’s refusal to subsidize Viroblax and its continued sale to Cadmex could be disastrous: it jeopardizes the continued existence of Viroblax, which is one of ten vaccine-resistant strains of Salmonella that have been approved for the treatment of Salmonella for several years now. Furthermore, in light of the recent outbreak of Salmonella in Candore and Cadmex’s decision to sell Viroblax to Cadmex, the United States Government should not be doing anything which would discourage the sale to Cadmex of its controversial vaccine, so this vaccine could be used for a future outbreak. If it is not, the threat to the safety of the Salmonella-resistant Salmonella virus would then only grow stronger. I would like to ask: How do you think Gentura’s refusal to market Viroblax is doing that?
To what extent are Gentura’s actions actually being used to ensure that Viroblax passes through the American public or to prevent it? How will the American public understand these actions being performed, as they often do? Is there some basis for them? How do you approach this issue?
I think the answer comes from a single public statement which summarizes a long-standing conversation among Gentura’s directors and representatives in which they discuss Viroblax administration in the community. During the meetings, some members discuss the following concerns about the role being played by Gentura and Cadmex:
(1) The decision by Gentura and Cadmex to sell Viroblax is an opportunity for non-Gentura partners to compete from the start.
(2) Viroblax has no proven medical basis to sell.
(3) Viroblax has been used for multiple outbreaks.
(4) Ventivitis, a form of contagious infection caused by Salmonella, is an increasingly common cause of death among children.
This group of concerns is echoed in multiple conversations with Gents in several other communities over the last several years. And as the conversation continues, the number of discussions, both public and private, has increased.
Given that the United States has a very high death toll from Salmonella outbreaks, it is clear Gentura’s lack of interest in these concerns leads it to be very vocal about being prepared to deal with these threats. And I would like to ask why in the absence of a serious effort to halt outbreaks the American public doesn’t engage on this subject.
In its statement, Gentura goes on to discuss the issue of the risk of outbreaks and suggests a policy to help encourage the spread of the new Salmonella-resistant strains of Salmonella. It says:
The U.S. government’s ongoing efforts to promote the safety of vaccines is essential to make sure such efforts are taking place with the help of private-sector partners. The federal government’s participation in such actions reflects the fact that this challenge is not just about vaccines. It is also about understanding
Gentura’s refusal to subsidize Viroblax and its continued sale to Cadmex could be disastrous: it jeopardizes the continued existence of Viroblax, which is one of ten vaccine-resistant strains of Salmonella that have been approved for the treatment of Salmonella for several years now. Furthermore, in light of the recent outbreak of Salmonella in Candore and Cadmex’s decision to sell Viroblax to Cadmex, the United States Government should not be doing anything which would discourage the sale to Cadmex of its controversial vaccine, so this vaccine could be used for a future outbreak. If it is not, the threat to the safety of the Salmonella-resistant Salmonella virus would then only grow stronger. I would like to ask: How do you think Gentura’s refusal to market Viroblax is doing that?
To what extent are Gentura’s actions actually being used to ensure that Viroblax passes through the American public or to prevent it? How will the American public understand these actions being performed, as they often do? Is there some basis for them? How do you approach this issue?
I think the answer comes from a single public statement which summarizes a long-standing conversation among Gentura’s directors and representatives in which they discuss Viroblax administration in the community. During the meetings, some members discuss the following concerns about the role being played by Gentura and Cadmex:
(1) The decision by Gentura and Cadmex to sell Viroblax is an opportunity for non-Gentura partners to compete from the start.
(2) Viroblax has no proven medical basis to sell.
(3) Viroblax has been used for multiple outbreaks.
(4) Ventivitis, a form of contagious infection caused by Salmonella, is an increasingly common cause of death among children.
This group of concerns is echoed in multiple conversations with Gents in several other communities over the last several years. And as the conversation continues, the number of discussions, both public and private, has increased.
Given that the United States has a very high death toll from Salmonella outbreaks, it is clear Gentura’s lack of interest in these concerns leads it to be very vocal about being prepared to deal with these threats. And I would like to ask why in the absence of a serious effort to halt outbreaks the American public doesn’t engage on this subject.
In its statement, Gentura goes on to discuss the issue of the risk of outbreaks and suggests a policy to help encourage the spread of the new Salmonella-resistant strains of Salmonella. It says:
The U.S. government’s ongoing efforts to promote the safety of vaccines is essential to make sure such efforts are taking place with the help of private-sector partners. The federal government’s participation in such actions reflects the fact that this challenge is not just about vaccines. It is also about understanding
In my opinion the Gentura situation should be handled in one of two ways. My first recommendation would be for Gentura to pay CadMex the agreed upon amount of money once they are stable enough to make such a payment. Gentura could also make the payments over time instead of in one lump sum so that they do not have to worry about going bankrupt. My second recommendation would be for Cadmex to allow the subsidization of Viroblax to take place